A Phase 2 interventional study of MORF-057 in Inflammatory Bowel Diseases and Colitis, Ulcerative, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Colitis, Ulcerative by Eli Lilly and Company — 5 open to participants now, 7 under way, 3 of them phase 3. Colitis, Ulcerative · Eli Lilly and Company.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 2, and was the 8th registered.
1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 16 studies in Colitis, Ulcerative by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Argentina, Brazil and 25 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Austria, Brazil and 14 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Austria, Belgium and 20 more countries
Ages 18–70
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
By country, each count listing its studies:
Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 70 across 1,238 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 211 across the 16 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), one of the names counted as Eli Lilly and Company. Under that name alone:
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
2 of the studies in Colitis, Ulcerative by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186101Eli Lilly and CompanyLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: | 2027-05 |
| NCT07483073Eli Lilly and CompanyA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)
The main part of this Phase 2a study will consist of 3 study periods: a Screening Period, a Treatment Period and a Safety Follow-up Period. All participants who complete the open-label Treatment Period will have the opportunity to continue their treatment in an optional 26-week Long-term Extension study after completing the Week 52 assessments.
1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
This study's enrollment of 39 is below the median of 70 across 1,238 interventional studies indexed under Colitis, Ulcerative.
Browse Colitis, Ulcerative studies →Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
First submitted before Morphic Therapeutic, Inc. became part of Eli Lilly and Company.
Compared within Colitis, Ulcerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received MORF-057 100 milligrams (mg) orally twice daily for up to 78 weeks.
Drug: MORF-057
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
Also known as: LY4268989
Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score
Robarts Histopathology Index (RHI) Score: the total RHI Score ranges from 0 (no disease activity) to 33 (severe disease activity)
Time frame: From baseline to 12 weeks
Main Cohort: Change From Baseline to Week 12 in the Modified Mayo Clinic Score
The Modified Mayo Clinic Score (mMCS) is a composite of the following Mayo Clinic Score subscores: Endoscopy subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration), Stool Frequency subscore (range: 0=Normal number of stools for this participant to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The total mMCS ranges from 0 to 9, with higher scores indicating more severe disease.
Time frame: From baseline to 12 weeks
Main Cohort: Maximum Plasma Concentration (Cmax) During Multiple Doses of MORF-057
To determine the Maximum Plasma Concentration of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.
Time frame: 12 weeks
Main Cohort: Time to Reach Cmax (Tmax) During Multiple Doses of MORF-057
To determine the Tmax of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.
Time frame: 12 weeks
Main Cohort: Area Under the Curve (AUC) Following Multiple Doses of MORF-057
To determine the area under the concentration-time curve of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.
Time frame: 12 weeks
The study plan included two cohorts. Both cohorts receive the same MORF-057 treatment regimen. * Main cohort for formal assessment of study objectives. Participants in this cohort were biologic-naïve or previously exposed to biologic therapies, with no prior vedolizumab exposure. * Exploratory cohort for exploratory purposes only and not used to assess the study objectives. Participants in this cohort had prior vedolizumab exposure with intolerance or secondary non-response.
| Milestone | MORF-057 (Main Cohort) | MORF-057 (Exploratory Cohort) |
|---|---|---|
| Started | 35 | 4 |
| Received at least one dose of study drug | 35 | 4 |
| Completed | 17 | 1 |
| Not completed | 18 | 3 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Lack of efficacy | 8 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 |
Robarts Histopathology Index (RHI) Score: the total RHI Score ranges from 0 (no disease activity) to 33 (severe disease activity)
| score on a scale | MORF-057 (Main Cohort) |
|---|---|
| Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score | -6.4 ± 11.18 |
The Modified Mayo Clinic Score (mMCS) is a composite of the following Mayo Clinic Score subscores: Endoscopy subscore (range: 0=Normal or inactive disease to 3=Severe disease (spontaneous bleeding, ulceration), Stool Frequency subscore (range: 0=Normal number of stools for this participant to 3=5 or more stools more than normal), and Rectal Bleeding subscore (range: 0=No blood seen to 3=Blood alone passed). The total mMCS ranges from 0 to 9, with higher scores indicating more severe disease.
| score on a scale | MORF-057 (Main Cohort) |
|---|---|
| Main Cohort: Change From Baseline to Week 12 in the Modified Mayo Clinic Score | -2.3 ± 2.14 |
To determine the Maximum Plasma Concentration of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.
| ng/mL | MORF-057 (Main Cohort) |
|---|---|
| Main Cohort: Maximum Plasma Concentration (Cmax) During Multiple Doses of MORF-057 | 766 ± 46.4 |
To determine the Tmax of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.
| hours | MORF-057 (Main Cohort) |
|---|---|
| Main Cohort: Time to Reach Cmax (Tmax) During Multiple Doses of MORF-057 | 2.014 ± 58.4534 |
To determine the area under the concentration-time curve of MORF-057, blood samples were collected per the study protocol at the following time points: Study Day 1 (first dose), predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 2, predose and 1, 2, 3, 4, and 6 hours post the AM dose; Week 6, predose and 1 and 3 hours post the AM dose; Week 12, predose and 1, 2, 3, 4, and 6 hours post the AM dose. On Study Day 1, Week 2, and Week 12, blood sampling for pharmacokinetics was optional at 8, 10, and 12 hours post the AM dose.
| hours*ng/mL | MORF-057 (Main Cohort) |
|---|---|
| Main Cohort: Area Under the Curve (AUC) Following Multiple Doses of MORF-057 | 3070 ± 45.7 |
Collected over From baseline to week 78. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MORF-057 (Main Cohort) | 0/35 (0%) | 0/35 (0%) | 19/35 (54.3%) |
| MORF-057 (Exploratory Cohort) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | MORF-057 (Main Cohort) | MORF-057 (Exploratory Cohort) |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 7/35 | 4/4 |
| AnaemiaBlood and lymphatic system disorders | 3/35 | 1/4 |
| Fungal skin infectionInfections and infestations | 0/35 | 1/4 |
| SinusitisInfections and infestations | 1/35 | 1/4 |
| ErythemaSkin and subcutaneous tissue disorders | 0/35 | 1/4 |
| HypertensionVascular disorders | 1/35 | 1/4 |
| Anal fistulaGastrointestinal disorders | 2/35 | 0/4 |
| Covid-19Infections and infestations | 2/35 | 0/4 |
| NasopharyngitisInfections and infestations | 2/35 | 0/4 |
| Upper respiratory tract infectionInfections and infestations | 2/35 | 0/4 |
All enrolled participants.
| Age, Continuous(years) | MORF-057 (Main Cohort) | MORF-057 (Exploratory Cohort) | Total |
|---|---|---|---|
| Mean | 39.2 ± 14.1 | 59.5 ± 14.36 | 41.3 ± 15.27 |
| Age, Customized(Participants) | MORF-057 (Main Cohort) | MORF-057 (Exploratory Cohort) | Total |
|---|---|---|---|
| 18 to 64 years | 34 | 2 | 36 |
| 65 to 84 years | 1 | 2 | 3 |
| Sex: Female, Male(Participants) | MORF-057 (Main Cohort) | MORF-057 (Exploratory Cohort) | Total |
|---|---|---|---|
| Female | 16 | 1 | 17 |
| Male | 19 | 3 | 22 |
| Ethnicity (NIH/OMB)(Participants) | MORF-057 (Main Cohort) | MORF-057 (Exploratory Cohort) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 34 | 4 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MORF-057 (Main Cohort) | MORF-057 (Exploratory Cohort) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 35 | 4 | 39 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | MORF-057 (Main Cohort) | MORF-057 (Exploratory Cohort) | Total |
|---|---|---|---|
| United States | 7 | 1 | 8 |
| Poland | 28 | 3 | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2022 to primary completion in Oct 2023, 18 months.
Results were first posted in Nov 2024, 1 year 1 month after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 18 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MORF-057
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) →